Objective: To describe clinical characteristics, course, and outcome during a 1-year period after the first manic episode in patients with bipolar disorder (BD).
B D is a serious psychiatric condition characterized by high rates of relapse, persistent subsyndromal morbidity, significant psychosocial dysfunction, elevated mortality owing to suicide, and increases incidence of serious medical disorders. Given this, an understanding of the course of BD from the disease onset is critical as it may contribute to the development of timely interventions with a potential reduction in morbidity and mortality. Interestingly, most of the information to date about the longitudinal course of BD primarily comes from tracking outcomes in people who have had multiple mood episodes with the inevitable confounding of the results by variables such as duration of illness, number of episodes, and medication effects. Nonetheless, these studies support the common clinical observation that the course of BD is not as benign as was once supposed. Even with access to modern medications, most patients with BD experience high levels of morbidity, spending almost one-half of the follow-up periods with mood symptoms, most of which are depressive. 1, 2 Further, BD is associated with persistent cognitive deficits, 3 changes in brain morphology, 4 and reduced quality of life. 5 While research has been increasingly directed toward defining the extent of these deficits, little is understood about the interactions between them and the course of the illness.
Relapses, switches, and recurrence of mood episodes are common in BD, with reported rates as high as 57% in maintenance studies. 6, 7 These findings, though, cannot exclude the confounding effect of multiple previous episodes, type of treatment, and adherence to treatment. More recently, a few studies that have examined course and outcome of BD in patients who have recently had their first manic episode showed that, like first-episode schizophrenia, first-episode mania carries with it a high risk of poor functional outcome. 8, 9 These studies also reported a high risk of suicide, high prevalence of comorbid diagnoses, and worse outcome with earlier age at onset. [10] [11] [12] A large retrospective study, which included 20 350 patients with affective disorders after their first hospital admission, showed that bipolar patients had a higher risk of recurrence than those with major depressive disorder. In the same sample, the long-term prognosis of BD remained poor in a significant proportion of patients as they experienced decreasing lengths of interepisode intervals with an increasing number of episodes. 13 More recent prospective studies of first episode bipolar patients reported recurrence rates of 40% in an adult sample 9, 14 and 54% in an adolescent sample. 11 However, these studies recruited patients after their first psychotic episode, from inpatient units or from early psychosis intervention programs. The selection of the most severe cases of BD with psychosis and with hospitalization restricts the generalizability of the findings to all patients with bipolar I disorder.
To overcome limitations from a research perspective of previous first-episode cohorts, STOP-EM was started at UBC and Vancouver General Hospitals. This project recruited patients with and without psychosis, with bipolar I disorder, hospitalized or not, after their first manic episode. The objective of this project was to gather more information concerning the clinical course and neurobiological changes in people with bipolar I disorder, in particular in the early phase. The study of first-episode manic patients provides an opportunity to determine outcome on a prospective basis and to ascertain whether cognitive and structural brain changes are present at disease onset, develop over the course of the illness, or are due to treatment variables. Additionally, the study of first-episode patients allows the interaction of these changes to be more reliably assessed.
In this report, we describe the project design and the characteristics of the first 53 patients enrolled, and we also examine the pattern of recurrence of mood episodes within 1 year of follow-up and clinical correlates. Data from neurocognitive testing, morphometric assessment, and functional outcomes will be presented in separate reports.
Methods
STOP-EM is a prospective study of clinical outcomes, health status, brain morphology, neurochemistry, cognitive functioning, quality of life, and functional outcomes in patients who have recently experienced their first bipolar manic episode, according to DSM-IV-TR criteria. This project started in July 2004 and has been recruiting actively since then. In our study, we will present the data on the first 53 patients enrolled until July 2007 and their outcomes over a 6-to 12-month follow-up period. Patients were recruited from UBC and Vancouver General Hospitals and affiliated sites as well as through referrals from physicians and psychiatrists. People aged between 14 and 35 years who were currently experiencing or had experienced a first manic episode within At the baseline assessment, all subjects had a comprehensive clinical interview by a board-certified psychiatrist. The diagnosis of BD-recent manic episode was established based on all the available clinical information and a Mini International Neuropsychiatric Interview. 15 Subjects who had previously undiagnosed or untreated manic symptoms were excluded. Subjects who had previous hypomanic episodes were included. The comorbidities were diagnosed according to DSM-IV-TR criteria based on all the available information. 16 Subjects enrolled in the program received open label maintenance treatment for BD from clinicians with expertise in management of mood disorders and familiar with the most recent clinical guidelines. 17, 18 Any new mood episodes were treated using best evidence-based practices. In addition to regular assessment of psychiatric status, medication monitoring, and supportive therapy, subjects were offered the opportunity to participate in a standardized 8-week group psychoeducation program. Subjects enrolled in the program were assessed as clinically indicated, and at a minimum of every 6 months for research purposes, during a 5-year follow-up period.
Psychiatric status was assessed using clinical rating scales, including the YMRS, 19 HDRS 29-item version, 20 MADRS, 21 BPRS, 22 and CGI-BP. 23, 24 The criteria for full symptomatic remission were YMRS and HDRS score of 8 or less. 25 The remission criteria only accounted for the previous 2 weeks of symptoms. Relapse and recurrence, defined as mood symptoms occurring within 8 weeks of syndromal recovery and occurring after remission, respectively, will be named recurrence from here on. Recurrence was considered if manic or depressive symptoms fulfilled DSM-IV-TR for a mood episode. 16 Syndromic remission from first manic episode was considered the starting point for the survival curves. Psychiatric and medical histories, and information about current and past medication use, were obtained using all available sources of information, including patient interview, completion of the Patient Health Survey 27 and, when available, collateral information from family members and health records. National Instititue of Mental Health Life Charts 28 were constructed, retrospectively detailing the subject's course of illness. Adherence was assessed through clinical interview and for analysis purposes;
one event of discontinuing medication against medical advice within the follow-up period was considered nonadherence.
The STOP-EM program and all of the procedures described in this report have received approval from the UBC Clinical Research Ethics Board. Written informed consent was obtained from all patients prior to any study procedures taking place.
Statistics
Statistical analyses were performed using SPSS software, version 13.0 (SPSS Inc, Chicago, IL). Descriptive statistics were used to report sociodemographic and clinical characteristics of the sample. Association between dichotomous variables was assessed with chi-square test or Fisher exact test when appropriate. Changes in mood symptoms over time, as per mood scales scores, were assessed with repeated measures ANOVA. The cumulative probability of recurrence of a mood episode during the 12 months following the recovery of a first manic episode was estimated using the Kaplan-Meier method (survival curve). In addition, the effect of potential predictors (based on existing literature) of recurrence and time to outcome event (any new mood episode) from entry into the program were calculated using Cox proportional hazards modelling. Predictors were entered by stepwise selection if associated with the event at a significance level of P < 0.10. Sex, age, education, overall age of onset (age at onset of first lifetime mood episode), psychosis within manic episode, length of illness, number of previous episodes, presence of any psychiatric comorbidity, were entered as predictors of outcome. As exploratory analyses, we estimated the survival function for manic and depressive episodes separately, where the time-to-event is the time to first recurrent manic episode or the time to first depressive episode, respectively. Multiple episodes were not taken into account in the survival modelling. These were exploratory analyses as the sample size restricted the power to detect smaller effect sizes and precluded meaningful stratifications. All statistical tests were 2-tailed and were carried out using a significance level of á = 0.05. Data are presented as means plus or minus standard deviation.
Results
Fifty-three patients were recruited to date. Among the 41 due for the 6-month follow-up, 35 completed the visit; of these, all 27 that were due for 1-year follow-up completed the visit. There were 6 dropouts; 2 moved out of commutable distance, 2 withdrew consent, and 2 were lost to follow-up. Descriptive demographics are shown in was 7.9 months. Among predictors of survival, earlier age of onset was the only variable that significantly predicted recurrence of mood episodes. However, the hazard ratio showed only a small (â = 1.119; P = 0.02) increase in survival time with later age of onset. When examined separately, the 1-year survival rates were 76% for a manic episode and 58.7% for a depressive episode. The mean time-to-event was 11 months for manic and 8.3 months for depressive episode.
Discussion
The data from the STOP-EM program showed that of the 53 patients with a first manic episode, 52.9% of the patients had experienced a depressive episode before their first manic episode. The mean length of illness was close to 3 years, when previous depressive and hypomanic episodes were included. Further, our data suggest that more patients achieve remission of manic symptoms than of depressive symptoms. Despite the low threshold criteria, nonadherence rates were only 37% and were consistent with data from previous studies. 26 Interestingly, rates of substance abuse in our sample were as high as 54% and were significantly associated with nonadherence to treatment. The findings also indicate a high relapse rate over a 1-year period, despite comprehensive clinical care that included evidence-based pharmacotherapy and psychoeducation, with only 46.7% of patients surviving without a mood episode. Among patients who had recurrence of symptoms, depression was responsible for most episodes. Among predictors of recurrence, age of onset was the only variable with significant association with the outcome.
Recurrence rates of 53% observed in this sample are consistent with survival rates reported in previous studies of first-episode patients. 11, 14 For instance, in a sample of adolescents who were hospitalized for a first-episode mania, of those who achieved syndromal recovery, 54% had a recurrence of a mood episode within a 12-month period. 11 Similarly, in the McLean first-episode cohort of hospitalized manic or mixed-episode patients, of those that attained syndromal recovery from the first manic episode, 40% had a recurrence, while 20% of the initial cohort switched into a depressive episode without recovery from mania. 14 Interestingly, the mean time to recurrence of a mood episode of 7.9 months was slightly longer in our sample, compared with the populations in previous reports. Tohen et al 14 reported a mean time to any mood episode of 6.5 months, to a manic episode of 8.1 months, and to a depressive episode of 7.9 months, 14 while De Bello et al 11 a P < 0.01; b P < 0.05; c P < 0.001; ANOVA repeated measures CGI-BP-S = Clinical Global Impression Scale for Bipolar Disorder-Severity; GAF = Global Assessment of Functioning; n/a = not applicable at baseline outcomes in adolescent cohorts may be due to poorer adherence to treatment as 65% of patients in that cohort were reported to be nonadherent to treatment. In contrast, despite low threshold for definition of nonadherence, the rates were only 37% in our sample. Many patients in our cohort received a group psychoeducation after enrolment, which may have contributed to better outcomes in our first-episode cohort.
Nonadherence rates in BD treatment for long-term prophylactic pharmacotherapy range from 18% to 52%, with a median prevalence of 44.7%. 29 Thus the 37% nonadherence rate in our sample is consistent with these previous reports. One reason for poor adherence to treatment is comorbidity with substance abuse disorder. A recent study described lifetime adherence rates of 65.5% for patients with BD with comorbid substance abuse disorder, compared with 82.5% for those without comorbidity. 30 Substance abuse was also a predictor of poor adherence to treatment in a sample of patients with BD followed after their first hospitalization, 31 similar to the results found in our cohort.
Our results also confirm findings from previous reports that earlier age of onset is associated with a worse outcome. In our sample, those with earlier age of onset presented a higher risk of recurrence of a mood episode. This is consistent with the recent perspective of BD as a developmental psychopathology. Between 50% and 66% of adults with BD experience illness onset before the age of 19 years, and between 15% to 28% before the age of 13 years. 32, 33 Childhood or adolescence onset of BD is associated with a more severe, adverse, and rapid cycling course of illness and multiple comorbidities. [34] [35] [36] [37] Long-term prospective studies suggest that of time spent symptomatic, patients with BDI experience depressive symptomatology about 3 times as frequently as hypomanic or manic symptoms. 38 Our findings confirm the importance of the depressive phase early in the course of BD, as depressive episodes in our cohort not only preceded the first manic episode but depressive recurrence was more common than manic recurrence. Depressive episodes preceding the first manic episode might have been underrecognized in previous studies that only examined episodes requiring hospitalization and reflect a common clinical challenge in the treatment of BD; the differential diagnosis with major depression, when mania has not yet occurred. This is of clinical relevance, as the deleterious impact of delay in the diagnosis of BD has been highlighted in previous reports. For example, the number of years that patients with BD go undiagnosed and without appropriate treatment is associated with worse quality of life and higher levels of depression. 39 Recent studies also report the negative effects of cumulative mood episodes. 40 Previous literature of maintenance studies suggests that polarity of index episode predicts the polarity of subsequent relapse. 41 For example, a randomized maintenance study of lamotrigine and lithium showed that, when the index episode was mania, about two-thirds of patients had higher ratio of relapse of mania, while, when the index episode was depression, all patients had a higher ratio of relapse of depression. 42 Similarly, for patients recovered from a bipolar depressive episode, the risk of relapse into depression is higher than the risk of relapse into mania within 1 year of follow-up, even if antidepressants were added to mood stabilizers. 43 However, in our sample recently treated for a manic episode, the recurrence of depressive episodes was most commonly observed. One reason for the discrepancy in findings may be that patients in our cohort were treated with one or more medications plus psychoeducation as clinically indicated, in contrast to clinical trials of maintenance treatment in which patients are usually not allowed to receive any psychosocial treatments or concomitant medications. That depressive recurrence was more common in our cohort, despite comprehensive evidence-based pharmacotherapy and psychosocial treatments, suggests that currently available treatments are less effective in preventing depression than in preventing mania. Indeed, there are studies showing that the magnitude of prophylactic efficacy is greater for preventing mania than depression for lithium 42, 44 and olanzapine, [45] [46] [47] and likely for many other psychotropic medications with the exception of lamotrigine.
While the index episode is considered the episode preceding the maintenance treatment, some studies examined the association of polarity of the first illness episode and polarity of relapse during maintenance treatments. Studies from the pre-lithium era suggested that if the first episode was manic, there was an increased risk of manic relapse. 41 In our sample, more than one-half of patients had a first episode of depression. However, there was no association between polarity of first episode and polarity of first recurrence during follow-up. Many of the earlier studies included only episodes of recurrence that required hospitalization, leading to a possible underestimation of depressive episodes.
Some limitations should be considered when interpreting these results. The sample size may have restricted the ability to detect smaller effect sizes of other variables in the Cox proportional hazards model. As most patients were taking both one mood stabilizer and one antipsychotic, the assessment of impact of treatment on outcomes and comparison between treatments was limited. The relatively short period of follow-up dictates that our conclusions should be limited to the early recovery phase of first manic episodes.
Conclusions
The findings suggest that depressive episodes are an important part of the clinical course of early phase BD. This is in line with longitudinal studies, which showed that depression constitutes the most time spent with affective symptoms, outstripping mania and hypomania by a ratio of 3:1. 42 The findings point out that syndromal remission may be easy to achieve but difficult to maintain; symptomatic remission is common in the early course of BD, but recurrence is also common. The effect of earlier age of onset on recurrence highlights the importance of preventive strategies and the need for studies with at-risk populations. The clinical features reported here reinforce the pressing need for improved understanding of the early course of BD, with special attention to the increased risk of depressive relapse.
